LIN28A and neoplasm: Inhibitors of specific RBPs, such as LIN28, IGF2BPs, HuR, and Musashi, have shown efficacy in decreasing tumor growth, enhancing the differentiation of cancer cells, and reducing resistance to chemotherapy.